Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Health Catalyst Inc (NASDAQ: HCAT) closed at $2.38 up 3.93% from its previous closing price of $2.29. In other words, the price has increased by $3.93 from its previous closing price. On the day, 0.54 million shares were traded. HCAT stock price reached its highest trading level at $2.39 during the session, while it also had its lowest trading level at $2.26.
Ratios:
For a deeper understanding of Health Catalyst Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 1.86. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.50.
Cantor Fitzgerald Downgraded its Overweight to Neutral on August 08, 2025, while the target price for the stock was maintained at $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 05 ’25 when Landry Benjamin sold 27,425 shares for $2.64 per share. The transaction valued at 72,328 led to the insider holds 100,000 shares of the business.
Larson-Green Julie sold 47,997 shares of HCAT for $128,349 on Dec 04 ’25. The Director now owns 73,573 shares after completing the transaction at $2.67 per share. On Dec 05 ’25, another insider, BENJAMIN LANDRY, who serves as the Officer of the company, bought 27,425 shares for $2.69 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 168339504 and an Enterprise Value of 248918496. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.53 while its Price-to-Book (P/B) ratio in mrq is 0.51. Its current Enterprise Value per Revenue stands at 0.788 whereas that against EBITDA is -14.775.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.74, which has changed by -0.6888587 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $7.65, while it has fallen to a 52-week low of $2.02. The 50-Day Moving Average of the stock is -9.83%, while the 200-Day Moving Average is calculated to be -29.63%.
Shares Statistics:
For the past three months, HCAT has traded an average of 647.67K shares per day and 576950 over the past ten days. A total of 70.62M shares are outstanding, with a floating share count of 62.38M. Insiders hold about 11.80% of the company’s shares, while institutions hold 78.15% stake in the company. Shares short for HCAT as of 1765756800 were 5223498 with a Short Ratio of 8.07, compared to 1763078400 on 6060201. Therefore, it implies a Short% of Shares Outstanding of 5223498 and a Short% of Float of 8.41.
Earnings Estimates
. The current rating of Health Catalyst Inc (HCAT) reflects the combined expertise of 8.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.08, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.25 and $0.18 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.35, with 10.0 analysts recommending between $0.62 and $0.21.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $73.94M this quarter.It ranges from a high estimate of $75.04M to a low estimate of $73.5M. As of. The current estimate, Health Catalyst Inc’s year-ago sales were $79.61MFor the next quarter, 11 analysts are estimating revenue of $74.3M. There is a high estimate of $76.4M for the next quarter, whereas the lowest estimate is $71.96M.
A total of 12 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.49M, while the lowest revenue estimate was $309.9M, resulting in an average revenue estimate of $310.26M. In the same quarter a year ago, actual revenue was $306.58MBased on 12 analysts’ estimates, the company’s revenue will be $302.08M in the next fiscal year. The high estimate is $307.5M and the low estimate is $298.1M.
